Review



mouse anti‐human mab against β subunit  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Merck & Co mouse anti‐human mab against β subunit
    Mouse Anti‐Human Mab Against β Subunit, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+mab+against+%CE%B2+subunit/pmc06151342-327-6-14?v=Merck+%26+Co
    Average 90 stars, based on 1 article reviews
    mouse anti‐human mab against β subunit - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    mouse anti‐human mab against β subunit  (Merck & Co)
    90
    Merck & Co mouse anti‐human mab against β subunit
    Mouse Anti‐Human Mab Against β Subunit, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+mab+against+%CE%B2+subunit/pmc06151342-327-6-14?v=Merck+%26+Co
    Average 90 stars, based on 1 article reviews
    mouse anti‐human mab against β subunit - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    monoclonal antibody against activin a  (R&D Systems)
    93
    R&D Systems monoclonal antibody against activin a
    Fig. 1. ActRIIA.muFc promotes osteoblastogenesis and increases bone mass. (A) Effect of activin-A, ActRIIA.muFc, and anti-activin-A antibody <t>(mab3381)</t> on mineralization. (B) TRACP-stained osteoclasts (blue arrows) and resorption pits (white arrows) in osteoclast cultures; addition of activin-A (0, 10, and 100 ng/mL) does not increase osteoclast number or bone resorption area. (C) Bone density of naive mice treated with increasing concentrations of ActRIIA.muFc at 6 weeks in the tibiaa. a ¼ p < .01 compared with vehicle. (D) mCT analysis of trabecular bone volume (BV/TV, %) and trabecular number (TB. N, /mm) of femurs of mice treated with ActRIIA.muFc. Lower, median, and higher quartiles are shown. b ¼ p < .001.
    Monoclonal Antibody Against Activin A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+mab+against+%CE%B2+subunit/pm20533325-43-17-23?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    monoclonal antibody against activin a - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1. ActRIIA.muFc promotes osteoblastogenesis and increases bone mass. (A) Effect of activin-A, ActRIIA.muFc, and anti-activin-A antibody (mab3381) on mineralization. (B) TRACP-stained osteoclasts (blue arrows) and resorption pits (white arrows) in osteoclast cultures; addition of activin-A (0, 10, and 100 ng/mL) does not increase osteoclast number or bone resorption area. (C) Bone density of naive mice treated with increasing concentrations of ActRIIA.muFc at 6 weeks in the tibiaa. a ¼ p < .01 compared with vehicle. (D) mCT analysis of trabecular bone volume (BV/TV, %) and trabecular number (TB. N, /mm) of femurs of mice treated with ActRIIA.muFc. Lower, median, and higher quartiles are shown. b ¼ p < .001.

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.

    doi: 10.1002/jbmr.142

    Figure Lengend Snippet: Fig. 1. ActRIIA.muFc promotes osteoblastogenesis and increases bone mass. (A) Effect of activin-A, ActRIIA.muFc, and anti-activin-A antibody (mab3381) on mineralization. (B) TRACP-stained osteoclasts (blue arrows) and resorption pits (white arrows) in osteoclast cultures; addition of activin-A (0, 10, and 100 ng/mL) does not increase osteoclast number or bone resorption area. (C) Bone density of naive mice treated with increasing concentrations of ActRIIA.muFc at 6 weeks in the tibiaa. a ¼ p < .01 compared with vehicle. (D) mCT analysis of trabecular bone volume (BV/TV, %) and trabecular number (TB. N, /mm) of femurs of mice treated with ActRIIA.muFc. Lower, median, and higher quartiles are shown. b ¼ p < .001.

    Article Snippet: Cells were incubated with vehicle (PBS), activin-A (20mg/m; R&D Systems, Minneapolis, MN, USA), ActRIIA.muFc (20mg/mL), or a monoclonal antibody against activin-A (mab3381, 10mg/mL; R&D Systems).

    Techniques: Staining